Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
CELU
Celularity Inc.
Celularity's core products are allogeneic placental-derived cell therapies produced via the IMPACT platform.
|
$34.97M |
$1.30
+0.78%
|
|
NXTC
NextCure, Inc.
NextCure's lead programs are Antibody-Drug Conjugates (ADCs), the core product modality of the company.
|
$34.55M |
$13.08
+1.63%
|
|
POCI
Precision Optics Corporation, Inc.
The business includes design and manufacture of components/subassemblies for medical devices, i.e., Medical Device Components.
|
$33.94M |
$4.41
+0.68%
|
|
RADX
Radiopharm Theranostics Limited
Core product category: Radiopharmaceuticals used for diagnostic imaging and therapy in oncology.
|
$33.93M |
$5.18
+0.68%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$33.08M |
$0.50
-3.10%
|
|
ANTX
AN2 Therapeutics, Inc.
Epetraborole and AN2-502998 are oral small-molecule therapeutics developed on the company's boron chemistry platform.
|
$32.79M |
$1.22
-2.80%
|
|
GTHP
Guided Therapeutics, Inc.
LuViva is a point-of-care diagnostic device used for cervical cancer screening, which aligns with Diagnostic Equipment.
|
$32.60M |
$0.39
|
|
OTLC
Oncotelic Therapeutics, Inc.
OT-101 is an antisense oligonucleotide targeting TGFB2, fitting the Oligonucleotide Therapeutics category.
|
$32.21M |
$0.08
|
|
RMTI
Rockwell Medical, Inc.
Rockwell Medical's core offerings are dialysis-related consumables (acid and bicarbonate concentrates, single-use bicarbonate cartridge, and at-home packs) used with dialysis equipment.
|
$31.84M |
$0.93
-1.57%
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$31.78M |
$3.09
+14.87%
|
|
DYAI
Dyadic International, Inc.
Company directly produces recombinant proteins and enzymes (e.g., RHSA, transferrin, DNase1, RNase inhibitors, FGF, lactalbumin, lactoferrin) for life sciences, diagnostics, and food/industrial uses.
|
$31.49M |
$0.85
-4.49%
|
|
NERV
Minerva Neurosciences, Inc.
Minerva focuses on neuropsychiatric drug development (roluperidone for schizophrenia negative symptoms).
|
$31.12M |
$4.46
+3.00%
|
|
RDGL
Vivos Inc.
RDGL's core offering is radiopharmaceutical therapy using Y-90 for targeted cancer treatment.
|
$31.10M |
$0.07
|
|
VNRX
VolitionRx Limited
VolitionRx's Nu.Q platform enables liquid biopsy cancer diagnostics by detecting nucleosome/epigenetic biomarkers in blood.
|
$30.74M |
$0.36
+26.22%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$30.39M |
$1.41
+1.08%
|
|
JUNS
Jupiter Neurosciences, Inc.
Direct product category: orally administered small-molecule therapeutics based on a resveratrol platform (JOTROL).
|
$29.91M |
$0.87
+0.74%
|
|
ELUT
Elutia Inc.
Elutia's EluPro is a cardiology device used with cardiac implanted electronic devices (CIEDs), directly tying to Cardiology Devices.
|
$29.59M |
$0.70
-0.37%
|
|
BRNS
Barinthus Biotherapeutics plc
Company is pivoting to immunology/inflammation therapeutics and is advancing T‑cell immunotherapies (SNAP-TI), with VTP-1000 for celiac disease as lead candidate.
|
$29.52M |
$0.72
-0.68%
|
|
BDMD
Baird Medical Investment Holdings Limited
BDMD is a medical device manufacturer focused on microwave ablation systems and related hardware, a core medical devices category.
|
$29.39M |
$1.16
-7.60%
|
|
BTAI
BioXcel Therapeutics, Inc.
BXCL501 is a small-molecule drug delivered as an oral dissolving film; fits 'Oral Small Molecule Therapeutics'.
|
$29.26M |
$2.04
-1.69%
|
|
NAII
Natural Alternatives International, Inc.
Direct contract manufacturing services for private-label vitamins, minerals, herbal and other health care products.
|
$29.00M |
$4.74
+2.16%
|
|
KTCC
Key Tronic Corporation
Vietnam medical device manufacturing capability highlighted, aligning with Medical Devices & Biometrics.
|
$28.98M |
$2.67
-3.61%
|
|
PSTV
Plus Therapeutics, Inc.
Core product: radiopharmaceutical therapy using Rhenium-186 nanoliposomes for CNS cancers.
|
$28.57M |
$0.29
+3.08%
|
|
DRIO
DarioHealth Corp.
Integrated Medical Devices & Biometrics (smart glucose meters and biofeedback sensors) are part of the offering.
|
$28.30M |
$12.07
-1.19%
|
|
RNTX
Rein Therapeutics Inc.
IPF/related fibrotic orphan indications classify Rein's lead assets as addressing a rare disease space.
|
$28.20M |
$1.23
+6.03%
|
|
MIRA
MIRA Pharmaceuticals, Inc.
Ketamir-2 is a novel oral small-molecule therapeutic targeting neuropathic pain, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$27.84M |
$1.47
+0.34%
|
|
BOLD
Boundless Bio, Inc.
The company is a biotechnology firm focused on oncology, developing ecDNA-directed cancer therapies, which places it in Biotech - Oncology.
|
$27.76M |
$1.25
-0.40%
|
Showing page 30 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
